These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
317 related articles for article (PubMed ID: 23035210)
1. Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidence. Di Martino MT; Leone E; Amodio N; Foresta U; Lionetti M; Pitari MR; Cantafio ME; Gullà A; Conforti F; Morelli E; Tomaino V; Rossi M; Negrini M; Ferrarini M; Caraglia M; Shammas MA; Munshi NC; Anderson KC; Neri A; Tagliaferri P; Tassone P Clin Cancer Res; 2012 Nov; 18(22):6260-70. PubMed ID: 23035210 [TBL] [Abstract][Full Text] [Related]
2. In vivo activity of miR-34a mimics delivered by stable nucleic acid lipid particles (SNALPs) against multiple myeloma. Di Martino MT; Campani V; Misso G; Gallo Cantafio ME; Gullà A; Foresta U; Guzzi PH; Castellano M; Grimaldi A; Gigantino V; Franco R; Lusa S; Cannataro M; Tagliaferri P; De Rosa G; Tassone P; Caraglia M PLoS One; 2014; 9(2):e90005. PubMed ID: 24587182 [TBL] [Abstract][Full Text] [Related]
3. Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth. Leone E; Morelli E; Di Martino MT; Amodio N; Foresta U; Gullà A; Rossi M; Neri A; Giordano A; Munshi NC; Anderson KC; Tagliaferri P; Tassone P Clin Cancer Res; 2013 Apr; 19(8):2096-106. PubMed ID: 23446999 [TBL] [Abstract][Full Text] [Related]
4. Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo. Morelli E; Leone E; Cantafio ME; Di Martino MT; Amodio N; Biamonte L; Gullà A; Foresta U; Pitari MR; Botta C; Rossi M; Neri A; Munshi NC; Anderson KC; Tagliaferri P; Tassone P Leukemia; 2015 Nov; 29(11):2173-83. PubMed ID: 25987254 [TBL] [Abstract][Full Text] [Related]
5. miR-137 and miR-197 Induce Apoptosis and Suppress Tumorigenicity by Targeting MCL-1 in Multiple Myeloma. Yang Y; Li F; Saha MN; Abdi J; Qiu L; Chang H Clin Cancer Res; 2015 May; 21(10):2399-411. PubMed ID: 25724519 [TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo anti-tumor activity of miR-221/222 inhibitors in multiple myeloma. Di Martino MT; Gullà A; Cantafio ME; Lionetti M; Leone E; Amodio N; Guzzi PH; Foresta U; Conforti F; Cannataro M; Neri A; Giordano A; Tagliaferri P; Tassone P Oncotarget; 2013 Feb; 4(2):242-55. PubMed ID: 23479461 [TBL] [Abstract][Full Text] [Related]
7. DNA-demethylating and anti-tumor activity of synthetic miR-29b mimics in multiple myeloma. Amodio N; Leotta M; Bellizzi D; Di Martino MT; D'Aquila P; Lionetti M; Fabiani F; Leone E; Gullà AM; Passarino G; Caraglia M; Negrini M; Neri A; Giordano A; Tagliaferri P; Tassone P Oncotarget; 2012 Oct; 3(10):1246-58. PubMed ID: 23100393 [TBL] [Abstract][Full Text] [Related]
8. MicroRNA-34a is a tumor suppressor in choriocarcinoma via regulation of Delta-like1. Pang RT; Leung CO; Lee CL; Lam KK; Ye TM; Chiu PC; Yeung WS BMC Cancer; 2013 Jan; 13():25. PubMed ID: 23327670 [TBL] [Abstract][Full Text] [Related]
9. MicroRNA-34a is a potent tumor suppressor molecule in vivo in neuroblastoma. Tivnan A; Tracey L; Buckley PG; Alcock LC; Davidoff AM; Stallings RL BMC Cancer; 2011 Jan; 11():33. PubMed ID: 21266077 [TBL] [Abstract][Full Text] [Related]
10. miR-30-5p functions as a tumor suppressor and novel therapeutic tool by targeting the oncogenic Wnt/β-catenin/BCL9 pathway. Zhao JJ; Lin J; Zhu D; Wang X; Brooks D; Chen M; Chu ZB; Takada K; Ciccarelli B; Admin S; Tao J; Tai YT; Treon S; Pinkus G; Kuo WP; Hideshima T; Bouxsein M; Munshi N; Anderson K; Carrasco R Cancer Res; 2014 Mar; 74(6):1801-13. PubMed ID: 24599134 [TBL] [Abstract][Full Text] [Related]
11. A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells. Leotta M; Biamonte L; Raimondi L; Ronchetti D; Di Martino MT; Botta C; Leone E; Pitari MR; Neri A; Giordano A; Tagliaferri P; Tassone P; Amodio N J Cell Physiol; 2014 Dec; 229(12):2106-16. PubMed ID: 24819167 [TBL] [Abstract][Full Text] [Related]
12. Synthetic miR-145 mimic inhibits multiple myeloma cell growth in vitro and in vivo. Zhang Q; Yan W; Bai Y; Xu H; Fu C; Zheng W; Zhu Y; Ma J Oncol Rep; 2015 Jan; 33(1):448-56. PubMed ID: 25369735 [TBL] [Abstract][Full Text] [Related]
13. A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells. Gullà A; Di Martino MT; Gallo Cantafio ME; Morelli E; Amodio N; Botta C; Pitari MR; Lio SG; Britti D; Stamato MA; Hideshima T; Munshi NC; Anderson KC; Tagliaferri P; Tassone P Clin Cancer Res; 2016 Mar; 22(5):1222-33. PubMed ID: 26527748 [TBL] [Abstract][Full Text] [Related]
14. Promises and challenges of MicroRNA-based treatment of multiple myeloma. Tagliaferri P; Rossi M; Di Martino MT; Amodio N; Leone E; Gulla A; Neri A; Tassone P Curr Cancer Drug Targets; 2012 Sep; 12(7):838-46. PubMed ID: 22671926 [TBL] [Abstract][Full Text] [Related]
15. miR-15a and miR-16 affect the angiogenesis of multiple myeloma by targeting VEGF. Sun CY; She XM; Qin Y; Chu ZB; Chen L; Ai LS; Zhang L; Hu Y Carcinogenesis; 2013 Feb; 34(2):426-35. PubMed ID: 23104180 [TBL] [Abstract][Full Text] [Related]
16. Evidence of novel miR-34a-based therapeutic approaches for multiple myeloma treatment. Zarone MR; Misso G; Grimaldi A; Zappavigna S; Russo M; Amler E; Di Martino MT; Amodio N; Tagliaferri P; Tassone P; Caraglia M Sci Rep; 2017 Dec; 7(1):17949. PubMed ID: 29263373 [TBL] [Abstract][Full Text] [Related]
17. Combined expression of miR-34a and Smac mediated by oncolytic vaccinia virus synergistically promote anti-tumor effects in Multiple Myeloma. Lei W; Wang S; Yang C; Huang X; Chen Z; He W; Shen J; Liu X; Qian W Sci Rep; 2016 Aug; 6():32174. PubMed ID: 27552933 [TBL] [Abstract][Full Text] [Related]
18. c-Myc, RMRP, and miR-34a-5p form a positive-feedback loop to regulate cell proliferation and apoptosis in multiple myeloma. Xiao X; Gu Y; Wang G; Chen S Int J Biol Macromol; 2019 Feb; 122():526-537. PubMed ID: 30389523 [TBL] [Abstract][Full Text] [Related]
19. Chitosan nanoparticle-mediated delivery of miRNA-34a decreases prostate tumor growth in the bone and its expression induces non-canonical autophagy. Gaur S; Wen Y; Song JH; Parikh NU; Mangala LS; Blessing AM; Ivan C; Wu SY; Varkaris A; Shi Y; Lopez-Berestein G; Frigo DE; Sood AK; Gallick GE Oncotarget; 2015 Oct; 6(30):29161-77. PubMed ID: 26313360 [TBL] [Abstract][Full Text] [Related]
20. MicroRNA-34a targets notch1 and inhibits cell proliferation in glioblastoma multiforme. Li WB; Ma MW; Dong LJ; Wang F; Chen LX; Li XR Cancer Biol Ther; 2011 Sep; 12(6):477-83. PubMed ID: 21743299 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]